Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Jennisch

Psychiatry Urbandale, IA Medical Doctor

NPI 1225133606 CMS profile 55276

6921 Hickman Rd Ste 2327, Urbandale, IA 50322

Open in the dashboard

General payments

$948,571

1,273 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Jennisch of Urbandale, IA is reported in the CMS Open Payments database as having received $948,571 across 1,273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $178,246 211
2024 General $148,730 183
2023 General $220,248 263
2022 General $140,601 193
2021 General $92,102 100
2020 General $25,777 42
2019 General $142,866 281

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Jennisch
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Charles Jennisch were reported at $178,246. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Charles Jennisch Psychiatry median Middle half National median
2019 $142,866 $184 $59–$605 $163
2020 $25,777 $119 $36–$372 $114
2021 $92,102 $143 $43–$576 $132
2022 $140,601 $153 $50–$590 $149
2023 $220,248 $170 $56–$651 $160
2024 $148,730 $179 $57–$673 $164
2025 $178,246 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $472,185 559 payments
  2. ITI, Inc. $149,884 181 payments
  3. Axsome Therapeutics, Inc. $134,134 165 payments
  4. Neurocrine Biosciences, Inc. $67,889 111 payments
  5. E.R. Squibb & Sons, L.L.C. $47,408 61 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $40,066 60 payments
  7. Janssen Pharmaceuticals, Inc $21,797 42 payments
  8. Allergan Inc. $8,216 37 payments
  9. Sunovion Pharmaceuticals Inc. $3,553 24 payments
  10. Alkermes, Inc. $1,353 3 payments
  11. Other $2,086 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $715,489 296 payments
  2. Consulting Fee $151,611 61 payments
  3. Travel and Lodging $62,891 450 payments
  4. Food and Beverage $17,684 462 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $750 1 payment
  6. Education $146 3 payments
Products named General payments · program years 2019–2025
  1. REXULTI $467,260 547 payments
  2. CAPLYTA $149,836 179 payments
  3. Auvelity $134,122 164 payments
  4. INGREZZA $67,889 111 payments
  5. Trintellix $39,699 50 payments
  6. COBENFY $26,077 40 payments
  7. SPRAVATO $21,770 41 payments
  8. VRAYLAR $8,036 37 payments
  9. ABILIFY MAINTENA $5,050 14 payments
  10. LATUDA $3,553 24 payments
  11. Other $8,159 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,206

Median for Psychiatry & Neurology: 100

Drug cost

$103,887

Median for Psychiatry & Neurology: $2,986

Branded share of claims

26.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zyprexa Olanzapine Brand 21 $22,337
Caplyta Lumateperone Tosylate Brand 13 $21,663
Auvelity Dextromethorphan Hbr/Bupropion Brand 15 $18,183
Trintellix Vortioxetine Hydrobromide Brand 19 $17,792
Bupropion Xl Bupropion Hcl Brand 81 $3,210
Vilazodone Hcl Generic 21 $2,977
Venlafaxine Hcl Er Venlafaxine Hcl Brand 100 $2,436
Clozapine Generic 27 $2,001
Duloxetine Hcl Generic 54 $1,618
Quetiapine Fumarate Generic 89 $1,602

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$67,567 — —
Auvelity
$59,071 15 —
INGREZZA
$12,822 — —
COBENFY
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record